

# A Critique of Differential Abundance Analysis, and Advocacy for an Alternative

Thomas P. Quinn<sup>1\*</sup>, Elliott Gordon-Rodriguez<sup>2</sup>, and Ionas Erb<sup>3</sup>

<sup>1</sup>Applied Artificial Intelligence Institute (A2I2), Deakin University, Geelong, Australia

<sup>2</sup>Department of Statistics, Columbia University, New York, USA

<sup>3</sup>Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain

\**contacttomquinn@gmail.com*

## Abstract

It is largely taken for granted that differential abundance analysis is, by default, the best first step when analyzing genomic data. We argue that this is not necessarily the case. In this article, we identify key limitations that are intrinsic to differential abundance analysis: it is (a) dependent on unverifiable assumptions, (b) an unreliable construct, and (c) overly reductionist. We formulate an alternative framework called *ratio-based biomarker analysis* which does not suffer from the identified limitations. Moreover, ratio-based biomarkers are highly flexible. Beyond replacing DAA, they can also be used for many other bespoke analyses, including dimension reduction and multi-omics data integration.

## 1 What is differential abundance?

*Differential abundance analysis* (DAA), by which we mean the statistical analysis of single features, is commonly used to analyze high-throughput sequencing experiments. The intuition behind DAA is simple: A feature – for example, the abundance of a gene – may be relevant to an experimental condition if it associates with that condition. One can think of DAA in terms of a generalized linear model:

$$\mathbf{y} \approx \phi\left(\beta_j \mathbf{x}_j + \beta_0\right), \quad (1)$$

where  $\mathbf{y}$  describes the experimental condition (e.g., case vs. control) and  $\mathbf{x}_j$  describes the abundance of gene  $j \in \{1, \dots, G\}$  as measured across  $i \in \{1, \dots, N\}$  samples.<sup>1</sup> The optional transformation  $\phi$  depends on the distribution of  $\mathbf{y}$ . If  $\mathbf{y}$  is binary,  $\phi$  may be a logistic transform. When appropriate, one could add covariates to adjust the model for potential confounders. A gene is said to have *differential abundance* (DA) if its effect size  $\beta_j$  exceeds some threshold, for example a cutoff based on a statistical test that gives an adjusted p-value less than 0.05.

In practice, the application of DAA is more nuanced. There exist (at least) 3 potentially conflicting notions of DA, depending on what  $\mathbf{x}_j$  actually describes. Differential abundance can be: *absolute* when  $\mathbf{x}_j$  describes the true abundances of a gene, *relative* when  $\mathbf{x}_j$  describes the proportional abundances of a gene, or *presential* when  $\mathbf{x}_j$  describes the presence or absence of a gene. Figure 1 shows how these notions of DA may disagree with one another.

<sup>1</sup>In practice, most popular implementations of DAA will treat the abundance of a gene as a dependent variable and the experimental condition as the independent variable (corresponding to a retrospective study). We instead treat the experimental condition as the dependent variable (corresponding to a prospective study) in order to align DAA more clearly with the algorithmic modelling culture, for example to predict a disease status as a function of gene expression. Note that, under standard assumptions, inference in the prospective and retrospective models is typically equivalent [1].

Data Type	Group 1			Group 2			Interpretation
Absolute	<b>a</b>	<b>b</b>	<b>c</b>	<b>a</b>	<b>b</b>	<b>c</b>	Group 2 has more Gene a
	0	0	53	15	0	93	
	5	2	28	27	0	107	
	14	0	47	14	7	65	
	13	0	33	0	5	88	
Proportional	<b>a</b>	<b>b</b>	<b>c</b>	<b>a</b>	<b>b</b>	<b>c</b>	Group 1 has more Gene a
	0	0	1	.14	0	.86	
	.14	.06	.80	.20	0	.80	
	.23	0	.77	.16	.08	.76	
	.28	0	.72	0	.05	.95	
Presential	<b>a</b>	<b>b</b>	<b>c</b>	<b>a</b>	<b>b</b>	<b>c</b>	Both Groups have same
	0	0	1	1	0	1	
	1	1	1	1	0	1	
	1	0	1	1	1	1	
	1	0	1	0	1	1	

Figure 1: There are (at least) 3 different notions of differential abundance, depending on what the underlying data represent. These notions may not agree with one another. For example, a gene that is absolutely over-abundant in one group may appear otherwise when viewed in proportional or presential terms. Complicating matters further, sequencing biases typically make absolute abundances unavailable.

Many methods for DAA have been proposed, e.g. [2, 3, 4, 5, 6, 7, 8], (and keep being proposed, e.g., [9, 10]) and several attempts have been made to systematically benchmark them against one another [11, 12, 13, 14, 15, 16, 17]. However, DAA has received little scrutiny at the highest level of consideration. It is largely taken for granted that DAA is, by default, the best first step when analyzing genomic data. We argue that this is not necessarily the case. This article has 3 aims: (1) To summarize three popular approaches to DAA; (2) To highlight some limitations intrinsic to these approaches; and (3) to formulate an alternative framework called *ratio-based biomarker analysis* that overcomes the limitations of DAA.

## 2 Three Approaches to Differential Abundance

There is a general consensus among bioinformaticians that DAA requires something more than a linear model: the abundances must first get *pre-processed* to adjust for systematic biases. The pre-processing step is often called a *normalization*. However, there are diverging opinions about how the data ought to be pre-processed [18] and what pre-processing steps ought to meet the definition of normalization [19].

To understand normalization, we first need to understand the biases found in high-throughput sequencing data. Dillies et al. [12] describe two kinds of biases: *intra-sample biases* which result in mis-measurement for individual genes, for example due to its length or GC content, and *inter-sample biases* which result in mis-measurement for individual samples. Put symbolically, the *observed abundance*  $x_{ij}$  for sample  $i$  and gene  $j$  is produced as a function of the *true abundance*  $x_{ij}^*$ , the gene-specific mis-measurement bias  $\theta_j$ , the sample-specific mis-measurement bias  $C_i$ , and some experimental noise  $\epsilon_{ij}$ :

$$x_{ij} = f(x_{ij}^*, \theta_j, C_i, \epsilon_{ij}). \quad (2)$$

The bias  $\theta_j$  is often safely ignored in DAA because it is assumed to have the same effect across all samples (though it can have a major impact on gross summary statistics like alpha diversity [20]). The bias  $C_i$ , called the *sequencing depth*, poses a greater problem for DAA. It causes each sample vector  $\mathbf{x}_i$  to have an unreliable total, meaning that the observed abundances are not the true abundances. Although technological advances (e.g., unique molecular identifiers used in single cell sequencing) can mitigate the impact of sequencing biases, their presence has a major effect on DAA: because the observed abundances are not the true abundances, absolute DA cannot be readily calculated. Thus, sequencing biases necessitate normalization.

How do bioinformaticians account for differences in sequencing depth? In our opinion, there are, generally speaking, 3 Schools of Thought:

- **Absolutism:** This approach intends to make the between-group differences for normalized abundances the same as the between-group differences for true abundances. It works by standardizing samples with an *ideal reference* called an *effective library size normalization factor*. Some analysts may instead use “spike-in” nucleotides as an experimentally-derived ideal reference [21, 22, 23, 24]. Either way, absolutist methods claim to measure *absolute DA*, though whether this happens will depend on the goodness of the normalization factor. An example null hypothesis would be that the normalized abundance of gene 1 (representing the true abundance) is the same for groups 1 and 2.
- **Proportionalism:** This approach intends to make all sample vectors sum to the same total. In other words, it ensures that  $\sum_j^G x_{ij} = \sum_j^G x_{hj}$  for any two samples  $i$  and  $h$ . This can be done by dividing out the sample sums to get proportions (sometimes expressed with a per-thousand or per-million denominator, e.g., TPM), or by rarefaction [25]. Of note, proportions (or their logarithm) can also arise from a careful distributional modelling of the transcriptional activity of the cell [26]. Proportionalist methods measure *proportional DA*, though this is sometimes conflated with *absolute DA*. An example null hypothesis would be that the proportion of gene 1 is the same for groups 1 and 2.
- **Compositionism:** This approach also intends to make all samples comparable along a common scale. It works by recasting sample vectors with respect to an internal “reference frame” that helps interpret any differences between samples [27]. The reference need not be an ideal reference. Most often, the geometric mean of the sample serves as the reference, though one could use an individual feature or feature set instead [28]. For simplicity’s sake, we focus on the centered log-ratio (clr) transform [29]:

$$\text{clr}(\mathbf{x}_i) = \log \left( \frac{[x_{i1}, \dots, x_{iG}]}{\sqrt[G]{\prod_{j=1}^G x_{ij}}} \right). \quad (3)$$

Any constant factor  $C_i$  would cancel between the numerator and denominator of the log-ratio. As such, the clr transform corrects for differences in sequencing depth (although it cannot correct for zeros caused by under-sampling [30]). Interestingly, the geometric mean resembles an effective library size normalization factor, and so the clr can (confusingly) also be considered a normalization [19]. An example null hypothesis would be that the transformed abundance of gene 1 is the same for groups 1 and 2. Whether the transformed abundances represent absolute abundances depends on whether the analyst considers the CLR to be a normalization. Traditionally, compositionists do not [31].

How do these Schools of Thought think about *normalization*? The proportionalists consider their methods to be normalizations because they claim to divide out a source of bias  $C_i$ . Some proportionalist methods try to adjust for the other source of bias  $\theta_j$  too, for example by dividing out fragment length (e.g., RPKM [32]). The absolutists consider their methods to be normalizations because their methods are used to estimate the true between-group differences in gene abundance. Absolutists may not consider proportionalist methods to be *bona fide* normalizations because an ideal reference is not used. Compositionists may also consider a method to be a normalization if it can be used to estimate the true between-group differences in gene abundance. The clr may or may not be considered a normalization, depending on the authors using it. Quinn et al. [19] make the distinction between a *clr transformation* and a *clr ‘normalization’* which, while mathematically equivalent, differ in the motivation behind their use. Figure 2 shows a Venn diagram of some positions held by the 3 Schools of Thought.




Figure 2: When it comes to differential abundance analysis, there are, generally speaking, 3 Schools of Thought. All Schools agree it is necessary to pre-process sequence count data before analysis. However, they differ in the philosophy and approach used for pre-processing. The Venn diagram identifies some beliefs held in common by the different Schools of Thought.

### 3 The Limitations of These Approaches

We argue that neither the absolutist, the proportionalist, nor the compositionist approaches are appropriate for all analyses. We have 3 reasons: (1) absolute DA requires unverifiable assumptions, (2) proportional DA is an unreliable construct, and (3) univariate models are overly reductionist. These limitations are explained below.

#### 3.1 Limitation 1: Absolute DA requires unverifiable assumptions

A normalization factor removes inter-dependence by serving as an ideal reference against which to compare the observed gene counts. Imagine we knew the identity of a true “house-keeping gene” that was equally present in all samples. For example, let gene  $c$  from the set  $[a, b, c]$  be an ideal house-keeper. By definition of being a house-keeper, the absolute value of  $c$  – and not its proportional value – is fixed. When a house-keeper is available, we can use its proportional value to make sense of the other genes in absolute terms. For example, we can analyze  $[a, b]$  conditional upon  $c$  [33], and if the ratio of, say,  $a$ -to- $c$  is bigger in one group, then  $a$  is *actually* more abundant. Thus, true house-keepers allow us to measure absolute DA.

When the identity of an ideal house-keeper is unknown, one could make a guess at calculating a synthetic “house-keeper” to serve the same purpose. Making this calculation requires making an assumption about the distribution of the data. Popular effective library normalizations like TMM [34] and DESeq2 [2] – as well as `clr` ‘normalization’ [19] – assume that the majority of genes remain unchanged between samples. Under this assumption, a measure of the central tendency of the samples, such as their geometric means or medians, will act like a good house-keeper (while having an additional advantage over single house-keepers in that individual gene fluctuations are averaged out). When the assumption holds, normalization factors, like ideal house-keeping genes, allow us to measure absolute DA.

Does it make sense to assume that the majority of genes remain unchanged between samples? Maybe. It is at least a parsimonious assumption. Our point is not to advise when and where the assumption holds; perhaps this judgement is best left to the scientist performing the experiment. Rather, our point is to highlight that the assumption itself – whether true or not – is not verifiable without extensive experimentation that goes beyond routine sequencing (c.f., [35]). In order to verify whether the majority of genes are unchanged, one would need prior knowledge about the majority of genes. This would require absolute quantification of gene abundance, which, if done by sequencing, would require a way to verify whether the majority of genes are unchanged. This, in turn, would require prior knowledge about the majority of genes (and so on).

Contrary to popular belief, the clr does not solve the unverifiable assumption problem. One can think of normalization as an attempt to find a reference that answers the question, “What is the ideal per-sample scaling factor?”. One could use compositional methods to answer this question [36]. When used this way, compositional methods like the clr also imply an assumption [37], even if it is less often acknowledged explicitly.

### 3.2 Limitation 2: Proportional DA is an unreliable construct

Gene counts obtained from sequencing are inter-dependent. A sequencer only has a limited number of reads available to count DNA molecules. When there are more DNA molecules than reads, genes compete with one another to be counted: an increase in the abundance of one gene will “steal” reads from the others, causing all other genes to appear less abundant.<sup>2</sup>

In other words, inter-dependence makes proportional DA an unreliable construct. When we measure differences in gene proportion between groups, it tells us very little about the gene itself. For 3 genes,  $[a, b, c]$ , the question as to whether the fraction of  $a$  differs between the groups will depend on the amount of  $b$  and  $c$ . As such, differences in  $a$  could appear and disappear just by changing the values of  $b$  and  $c$ . In fact,  $a$  could show proportional DA even when it is equally present in all samples! When looking at genes in isolation, one can easily construct such examples where the change in proportion will tell you the opposite of the change in gene transcription. Figure 1 gives a thorough example.

It is sometimes argued that molecular proportions are all that count for the stoichiometry of the cell (or that microbial proportions are all that count for the community of a microbiome), and thus we should make proportions the basis of analysis. However, turning gene counts into proportions does *not* remove the inter-dependence. In fact, as proportions, genes must again compete for representation within the fraction: having more of one gene will cause the percentage of all other genes to decrease too. This is sometimes called the unit-sum constraint because the data are constrained to sum to one unit [39, 40]. Data that are subject to a unit-sum constraint are *compositional* [31]. Yet, it has been argued that the data cannot be considered *compositional* because there is always a substantial and variable proportion of reads that cannot be annotated [41]. However, incompletely annotated data are still *compositional* because the cause of the unit-sum constraint – i.e., the competition for representation within a sample – remains in effect. For example, the gene set  $[a, b, c]$  would still be interdependent regardless of whether a fourth gene  $[d]$  was measured. We do not think that the classical compositional treatment of rock samples is fundamentally different from the compositional modelling of sequencing experiments (a similarity that is suggested by the analogous units of parts per million vs. reads per million).<sup>3</sup>

Contrary to popular belief, the clr does not solve the inter-dependence problem. Although proportions transformed by the clr have real number values, they are not free to take arbitrary values: their sum must equal zero (geometrically speaking, they fall on a hyperplane in the space of the absolute data). When we consider the clr transformation of  $[a, b, c]$  – which we denote  $[a', b', c']$  – the value of  $a'$  still depends on  $b$  and  $c$ . Like with proportions, differences in  $a'$  could appear and disappear just by changing the values of  $b$  and  $c$ .

### 3.3 Limitation 3: Univariate models are overly reductionist

Beyond the more nuanced mathematical arguments against DAA, there are some good biological reasons to seek alternatives. We consider two related reasons: DAA is overly reductionist and

---

<sup>2</sup>For some low biomass samples, there may be more reads than DNA molecules, which may allow the analyst to quantify absolute gene abundances [38].

<sup>3</sup>In fact, there is a simple analogy between the mass of each part in a geochemical sample and the reads of a sequencing experiment mapped to different microbial genomes. We can compare the total number of reads before mapping to the weight of the rock sample analyzed. A single read mapped to a gene or microbial genome then corresponds to the minimum amount of an oxide or other chemical compound present in the rock sample that our technology allows us to detect (e.g., if the spectrometer allows a detection of 1 part per million, this unit would get multiplied with the mass of the input material). In chemical analysis, the only substances that can be detected are those that are queried for, in the same way that only microbes can be detected whose references are available for mapping. It does not matter here that the total number of mapped reads is not predetermined for each sample (the same way that the summed weights of all substances we query for isn't a random variable of interest). Although the sequencing experiment delivers read counts whereas the compounds in a rock sample are directly assigned densities via spectroscopy, we could, in principle, recast these densities as counts of detectable units. Clearly, the genomic counts will be fewer and the number of assigned and unassigned parts greater, but the qualitative aspect of our analogy remains intact.

furthermore ignores biological stoichiometry.

First, DAA is overly reductionist. In cells, gene products (i.e., proteins) do not work in isolation. They coordinate with one another to form highly organized functional modules, for example by defining a sequence of chain reactions in a metabolic pathway [42, 43]. Within an ecosystem, including a microbiome sample, species are likewise linked, competing for representation within ecological niches. Microbes also cooperate with one another, and with their hosts [44], to form symbiotic ecological communities, where some species “cross-feed” off the metabolic products of others [45]. While DAA fails to model *technical interdependence*, it also fails to model this *biological interdependence*.

Second, DAA ignores biological stoichiometry, which is broadly defined as the study of the balance of energy and multiple chemical elements in living systems [46]. In cells, RNA production capacity varies with the size of the cell, whereby two cells of the same type could have vastly different amounts of total RNA without any difference in phenotype [47]. Yet, a duplication of just some chromosomes tends to be more deleterious than a duplication of all chromosomes, suggesting that a change in *gene balance* causes more harm than a change in total *gene dosage* [48, 49]. In ecosystems, species within a niche have in common similar nutrient requirements, meaning that the stoichiometry of nutrients is a key aspect of their ecological niche [46, 50]. Likewise, the stoichiometry of species – or the *entropy* thereof, known in ecology as a type of *diversity* [51] – can itself describe an ecosystem [52]. For example, the total health of the gut microbiome – itself an ecosystem – may associate with the stoichiometry of Firmicutes species to Bacteroidetes species [53, 54]. DAA cannot model these stoichiometric complexes.

Mesoscale descriptors like modules and communities help define a unit of analysis that strikes a useful compromise between overly reductionist microscale descriptors (e.g., gene-level differential abundance) and overly broad macroscale descriptors (e.g., gene co-expression network topology) [55]. Existing methods like functional network analysis [56], multivariable ordination [57], and pathway scoring [58] can establish mesoscale features that describe the data more comprehensively than individual gene abundances. Meanwhile, biological stoichiometry offers another lens through which to understand living systems, including molecular and ecological interactions. Both perspectives are missing from DAA, but are present in our alternative framework.

## 4 An Alternative Framework

We agree with recent literature that recommends the use of ratios, especially sparse ratios, for the statistical analysis of gene expression and microbial abundance [59, 60, 61, 62, 63, 64]. Building on these works, we formulate an alternative framework called *ratio-based biomarker analysis* that solves the 3 limitations of DAA:

1. Ratio-based biomarkers are reliable constructs. Given a composition  $[a, b, c]$ , the value of  $c$  has no influence on the ratio  $\log \frac{a}{b}$ . Meanwhile, the log-scale presents itself as a natural choice for proportional data. It leaves the absolute value of the ratio unchanged when exchanging the numerator with the denominator, while further reducing the observed skew in the abundance distributions. It also turns products into sums, thus allowing a simple additive model to capture multiplicative interactions among stoichiometric complexes.
2. Ratio-based biomarkers do not require unverifiable assumptions. The denominator serves as a reference against which to interpret the numerator. This reference can be used in place of a normalizing reference. The reference need not be an ideal reference.
3. Ratio-based biomarkers are less reductionist. Ratio-based biomarkers establish mesoscale descriptors that measure the activity of some genes (the numerator) with respect to other genes (the denominator). By definition, ratio-based biomarkers describe stoichiometry.

The simplest ratio-based biomarker is a *pairwise log-ratio*, where the numerator and denominator each contain only 1 gene. Just as DAA measures the association between an outcome and a gene, *differential ratio analysis* measures the association between an outcome and a gene ratio [7, 65, 66], where a statistical test is performed for each pairwise log-ratio (with or without a subsequent summary step that distills the results into gene-level attribution scores).<sup>4</sup>

---

<sup>4</sup>Note that having  $p$  genes implies  $p(p-1)/2$  unique ratios and thus  $O(p^2)$  statistical tests, making pairwise log-ratio analyses vulnerable to Type II errors following p-value adjustment.

It is sometimes desirable to produce multi-part ratio biomarkers, containing 2 or more genes in the numerator or denominator. Several methods exist for *aggregating* genes, by which we mean *combining input features to form new composite features*. Figure 3 arranges aggregation methods along two descriptive axes. The first axis describes the aggregation rule: Are features aggregated based on prior expert knowledge (e.g., by grouping bacteria by phylogeny)? Or are they aggregated using an algorithm that finds patterns in the data (e.g., by machine learning)? The second axis describes the operation used to aggregate the parts: Are features aggregated by addition (e.g., arithmetic mean)? Or are they aggregated by multiplication (e.g., geometric mean)?

Ratio-based biomarker analysis is algebraically straightforward, and several open-source software tools already exist to implement this analysis. Below, we survey existing methods, and discuss how the flexibility of ratio biomarkers allows them to be used many other bespoke analyses, including dimension reduction and multi-omics data integration.




Figure 3: It is helpful to classify aggregation methods along two descriptive axes. The first describes the aggregation rule: expert-based vs. data-driven. The second describes the operation: addition vs. multiplication. Ratio-based biomarkers based on addition are called summed log-ratios, while ratio-based biomarkers based on multiplication are called balances.

#### 4.1 Aggregation by product

When features are aggregated by multiplication, the resulting ratio-based biomarker corresponds to a log-linear combination of variables (with coefficients summing to zero to ensure scale invariance). We highlight an important special case: when the numerator and denominator of our ratio correspond to simple geometric means of one or more features. Such ratios are called *balances* [67], and can be written as:<sup>5</sup>

$$\begin{aligned}
 z_i &= \log \left( \frac{(\prod_{j \in J^+} x_{ij})^{\frac{1}{G^+}}}{(\prod_{j \in J^-} x_{ij})^{\frac{1}{G^-}}} \right) \\
 &= \frac{1}{G^+} \sum_{j \in J^+} \log x_{ij} - \frac{1}{G^-} \sum_{j \in J^-} \log x_{ij},
 \end{aligned} \tag{4}$$

where  $J^+$  and  $J^-$  denote two disjoint sets of genes, of sizes  $G^+$  and  $G^-$ , respectively. Although the equation may look daunting, it just describes a log-ratio between two geometric means, where each average is the average of one gene set. There is one balance score  $z_i$  for each sample  $i$ , and together they form a new feature vector  $\mathbf{z}$ . Balances can be constructed according to a mathematical rule [68, 67] that one can derive from prior knowledge [60, 61] or from the data itself [69, 59, 64].

<sup>5</sup>Note that the original definition involves a prefactor as balances are related to orthonormal bases of the simplex. The prefactor is practically unnecessary for balance selection, as it would get absorbed into the regression coefficient.

Having fewer genes within each set would constitute a sparser balance, reducing the cognitive load required for interpretation. Sparsity is also advantageous from a statistical point of view, typically helping to prevent model overfit. The special case where  $G^+ = G^- = 1$  reduces to the pairwise log-ratio between two individual genes. Balances therefore define a strictly greater class of features, offering the potential for much more flexible families of models.<sup>6</sup> Note that any scaling factor applied to  $\mathbf{x}_i$  cancels out in the ratio of Eq. 4, and so balances are the same for both relative and absolute data.

Recently, interest has gathered around *balance selection*, which involves identifying maximally predictive balances algorithmically [62, 64, 70, 71]. The `selbal` algorithm uses forward stepwise linear regression to identify a single balance associated with an experimental condition [62]. We can express the final model by analogy to the generalized linear model used in DAA

$$\mathbf{y} \approx \phi(\beta \mathbf{z} + \beta_0). \quad (5)$$

The balance feature  $\mathbf{z}$  is *predictive* if its effect size  $\beta$  exceeds some threshold. In practice, the strategy for *validating* the association follows from the algorithmic modelling culture, where test set verification is used to measure out-of-sample model performance empirically [72] (i.e., instead of reporting a p-value). The `selbal` package makes balances easy to learn on low-to-moderate dimensional data ( $G < 100$  genes).

```
devtools::install_github(repo = "UVic-omics/selbal")
library(selbal)
model <- selbal(train.x, train.y)
yhat <- predict(model, test.x)
```

As for larger, high-dimensional data sets ( $100 < G < 100,000$  genes), a recent method called `codacore` achieves much the same goal more efficiently [71]. This method uses back-propagation with a network-inspired architecture instead of stepwise regression, resulting in fast runtimes on very high-dimensional data sets. In addition, `codacore` features a single regularization term, controlled by the argument `lambda`, which can be used to control the sparsity of the learned balances.

```
devtools::install_github(repo = "egr95/R-codacore", ref="main")
library(codacore)
model <- codacore(train.x, train.y, lambda = 1)
yhat <- predict(model, test.x)
```

Like with `selbal`, any learned balance should be validated using test set verification. If the balance achieves good predictive accuracy in an external test set, then it can be considered a *bona fide* ratio-based biomarker, and interpreted in place of univariate DAA results.

## 4.2 Aggregation by sum

The summing of parts is called an *amalgamation*. A ratio-based biomarker using amalgamations is called a *summed log-ratio* (SLR) [73, 74]. An SLR has the form

$$z_i = \log \left( \frac{\sum_{j \in J^+} x_{ij}}{\sum_{j \in J^-} x_{ij}} \right), \quad (6)$$

where again,  $J^+$  and  $J^-$  denote two disjoint sets of genes. As above, having fewer genes in each set results in a sparser ratio that is arguably easier to interpret. Like balances, there is one SLR score for each sample, and together they form a new feature vector  $\mathbf{z}$ .

SLRs were proposed to solve two perceived limitations with balances [75]. First, a log-ratio of geometric means – upon which balances depend – is undefined if any element equals zero. Such zeros are handled naturally by the sum. Second, a log-ratio of geometric means is not a “balance” in the plain English sense of the word and small values have a strong influence on the outcome. A *balance*, as in a *scale*, compares the *additive* – not *multiplicative* – totals of two sets.

Although the SLR was conceived separately from the genomics literature, it is already familiar to our field. For example, the Firmicutes-to-Bacteroidetes ratio, studied as a biomarker for obesity [53, 54], is a ratio between disjoint sets of bacteria taxa aggregated by sum based on their respective

<sup>6</sup>Given  $G$  input genes, one can derive  $\sim G^2$  pairwise log-ratios, but  $\sim (2^G)^2$  balances, a vastly greater number.

phyla membership. The log of this ratio is an SLR, whose association with an outcome could be expressed by analogy to the generalized linear model used in DAA.

$$\mathbf{y} \approx \phi(\beta\mathbf{z} + \beta_0). \quad (7)$$

An SLR feature  $\mathbf{z}$  is *predictive* when its effect size  $\beta$  exceeds some threshold, and is validated empirically using out-of-sample model performance.

In the case of the Firmicutes-to-Bacteroidetes SLR, the aggregation rule is defined by prior expert knowledge about microbe phylogeny. Like balances, it is possible to establish data-driven SLRs too, with recent studies proposing new methods for SLR selection. The `amalgam` package uses evolutionary algorithms to identify an SLR that optimizes a regression fit [76].

```
devtools::install_github(repo = "tpq/amalgam")
library(amalgam)
model <- amalgam(train.x, train.y, asSLR = TRUE, n.amalgam = 2)
yhat <- predict(model, test.x)
```




Figure 4: A high-level overview of how algorithms can learn predictive ratio-based biomarkers. First, the input data are used to randomly initialize a ratio-based biomarker. Next, the biomarker score is regressed against a continuous or categorical outcome, and a loss function is used to summarize the goodness of the fit. Finally, the algorithm constructs a new ratio-based biomarker and the cycle repeats. Once the fit is adequate, the algorithm stops and the best biomarker is returned. Different optimization algorithms can be used to find the best biomarker.

The `codacore` package can also learn SLRs by setting the argument `logRatioType="SLR"` [71]. As before, this method enjoys fast runtimes on very high-dimensional data sets, and tends to find very sparse biomarkers.

```
model <- codacore(train.x, train.y, logRatioType = "SLR", lambda = 1)
yhat <- predict(model, test.x)
```

We refer our readers to [71] for a systematic benchmark of balance selection, SLR selection, and other state-of-the-art methods.

## 5 The Flexibility of Ratio Biomarkers

Ratio-based biomarkers (RBB) are highly flexible. Beyond replacing DAA, they can be further used for many other bespoke analyses. In this section, we show how RBB can add value to dimension

reduction and multi-omics data integration alike, bringing greater interpretability to multivariable models. Our goal here is not to introduce new methodology; rather, we aim to unify conventional multivariable analysis with our proposed RBB framework.

It is increasingly common to collect multiple “-omics” data sets, e.g., microbe abundances and metabolite abundances [77, 78, 79, 80, 81]. In addition to analyzing each of the data sets separately, one could perform a single analysis of the combined data, revealing associations within and between the different modalities [82, 83, 84, 85]. In multi-omics data integration, the task is complicated because both data sets contain their own intra-sample and inter-sample biases [86]. Intuitively, each data set should get normalized separately before an analysis [87, 88], for example by using the `clr`. However, if we accept that a single normalization is problematic, then we might agree that the use of two normalizations is doubly problematic [88].

As a flexible framework, RBB can be leveraged to learn multivariable biomarkers that do not depend on normalization factors. For example, given the microbe abundances  $\mathbf{T}$  and metabolite abundances  $\mathbf{U}$ , we could learn a microbe ratio  $\mathbf{z}_t$  and a metabolite ratio  $\mathbf{z}_u$  that are highly correlated. Together, they would form a pair of ratio-based biomarkers that describe the commonality between two modes of data, e.g., a bacteria stoichiometry that is maximally predictive of a metabolite stoichiometry. The interpretation of these  $\mathbf{z}$  would not depend on any normalization factors by definition of them being scale-invariant log-ratios.

We extend RBB to multivariable applications by learning sparse and interpretable ratio biomarkers that serve as drop-in replacements for other low-dimensional latent representations. Put symbolically, we simply regress:

$$\mathbf{h} \approx \beta \mathbf{z} + \beta_0 \tag{8}$$

where the RBB  $\mathbf{z}$  is a replacement for the latent component  $\mathbf{h}$ . This approach can be used for dimension reduction (e.g., when  $\mathbf{T}$  is regressed onto a function of  $\mathbf{T}$ , or  $\mathbf{U}$  onto  $\mathbf{U}$ ), or for multi-omics data integration (e.g., when  $\mathbf{T}$  is regressed onto a function of  $\mathbf{U}$ , or  $\mathbf{U}$  onto  $\mathbf{T}$ ).

Table 5 compares the performance of several multivariable RBB algorithms, based on either (a) principal components analysis (PCA), (b) partial least squares (PLS) regression, or (c) neural network (NN) encoder-decoders.<sup>78</sup> With each algorithm, a (non-sparse) latent representation of the data is learned using off-the-shelf libraries. This representation is then approximated with a sparse RBB, using the `codacore` package. Finally, the original latent representations as well as the RBB approximations are used to reconstruct the original data, and the proportion of variance explained ( $R^2$ ) is measured. We find that the RBB approximations are similarly powerful to the original representations, while enjoying robustness against normalization biases as well as a high level of sparsity, thus dramatically enhancing model interpretability. Our Appendix presents an in-depth and reproducible case study of the PLS example, combining the `codacore` [71] and `mixOmics` [90] packages into a single analysis.

<sup>7</sup>For this benchmark, we use paired microbiome and metabolome abundance data, made publicly available by [81]. The data are lightly pre-processed by (a) removing any feature with  $> 50\%$  zero values and (b) replacing the remaining zeros with one half the detection limit. See [89] for a comparison of zero replacement strategies.

<sup>8</sup>Our encoder-decoder network architecture consists of an encoder mapping the input to a 1-dimensional latent space, and a decoder mapping the latent variable to the output. For simplicity, our encoder and decoder each have a single hidden layer with 32 units and ReLU nonlinearities.

Objective	1-D latent representation	Original $R^2$	RBB source	RBB # vars	RBB $R^2$
Dimension reduction	$\mathbf{h} = \text{PCA}_1(\text{clr}(\mathbf{T}))$	0.31	$\mathbf{T}$	18 / 58	0.31
	$\mathbf{h} = \text{PCA}_1(\text{clr}(\mathbf{U}))$	0.34	$\mathbf{U}$	5 / 7156	0.33
Multi-omics integration	$\mathbf{h} = \text{PCA}_1(\text{clr}(\mathbf{U}))$	0.34	$\mathbf{T}$	4 / 58	0.31
	$\mathbf{h} = \text{PCA}_1(\text{clr}(\mathbf{T}))$	0.31	$\mathbf{U}$	3 / 7156	0.27
Dimension reduction	$\mathbf{h} = \text{PLS}_1^{(\mathbf{T})}(\text{clr}(\mathbf{T}), \text{clr}(\mathbf{U}))$	0.30	$\mathbf{T}$	18 / 58	0.30
	$\mathbf{h} = \text{PLS}_1^{(\mathbf{U})}(\text{clr}(\mathbf{T}), \text{clr}(\mathbf{U}))$	0.35	$\mathbf{U}$	8 / 7156	0.34
Multi-omics integration	$\mathbf{h} = \text{PLS}_1^{(\mathbf{U})}(\text{clr}(\mathbf{T}), \text{clr}(\mathbf{U}))$	0.35	$\mathbf{T}$	6 / 58	0.31
	$\mathbf{h} = \text{PLS}_1^{(\mathbf{T})}(\text{clr}(\mathbf{T}), \text{clr}(\mathbf{U}))$	0.26	$\mathbf{U}$	19 / 7156	0.31
Dimension reduction	$\mathbf{h}$ , where $\mathbf{T} \xrightarrow{NN} \mathbf{h} \xrightarrow{NN} \mathbf{T}$	0.35	$\mathbf{T}$	20 / 58	0.31
	$\mathbf{h}$ , where $\mathbf{U} \xrightarrow{NN} \mathbf{h} \xrightarrow{NN} \mathbf{U}$	0.40	$\mathbf{U}$	7 / 7156	0.35
Multi-omics integration	$\mathbf{h}$ , where $\mathbf{T} \xrightarrow{NN} \mathbf{h} \xrightarrow{NN} \mathbf{U}$	0.39	$\mathbf{T}$	7 / 58	0.30
	$\mathbf{h}$ , where $\mathbf{U} \xrightarrow{NN} \mathbf{h} \xrightarrow{NN} \mathbf{T}$	0.34	$\mathbf{U}$	3 / 7156	0.28

Table 1: Proportion of variance explained ( $R^2$ ) for the top latent component from PCA, PLS, and NN encoder-decoders. For each latent representation, we show the  $R^2$  obtained by the original model alongside a single RBB optimized to approximate that representation. Generally speaking, the  $R^2$  values largely agree. Yet, based on the number of active variables, the RBB can achieve 65%-99% greater sparsity than a completely dense model. While we do consider several multivariable applications of RBB, the table is by no means exhaustive.

## 6 Summary

A critical examination of differential abundance analysis (DAA) reveals intrinsic limitations that researchers should seriously consider prior to using DAA. We advise that when using DAA, researchers should explicitly acknowledge the implicit assumptions they make, and recognize that the constructs used for hypothesis testing may be confounded by inter-dependence. Alternatively, they may wish to use ratio-based biomarkers instead. These ratios provide an intuitively simple alternative that does not suffer from the limitations of DAA. Ratio-based biomarkers require no normalization and cannot be confounded by interdependence. Advantageously, the framework is highly flexible and can be readily used for bespoke analyses to discover sparse, interpretable stoichiometric complexes that (co-)vary across time or space or experiment. The myriad of ways in which RBB can be used to analyze genes, the microbiome, their metabolites, and other “-omes” presents our field with many exciting research opportunities.

## 7 Availability of data and code

The data and benchmark analysis are available from <https://zenodo.org/record/4692004>.

## 8 Acknowledgements

TPQ thanks Thomaz Bastiaanssen for helpful discussions on theoretical ecology.

## References

- [1] R. L. PRENTICE and R. PYKE. Logistic disease incidence models and case-control studies. *Biometrika*, 66(3):403–411, December 1979.
- [2] Simon Anders and Wolfgang Huber. Differential expression analysis for sequence count data. *Genome Biology*, 11:R106, October 2010.

- [3] Mark D. Robinson, Davis J. McCarthy, and Gordon K. Smyth. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*, 26(1):139–140, January 2010.
- [4] Andrew D. Fernandes, Jean M. Macklaim, Thomas G. Linn, Gregor Reid, and Gregory B. Gloor. ANOVA-Like Differential Expression (ALDEx) Analysis for Mixed Population RNA-Seq. *PLOS ONE*, 8(7):e67019, July 2013.
- [5] Joseph N. Paulson, O. Colin Stine, Héctor Corrada Bravo, and Mihai Pop. Differential abundance analysis for microbial marker-gene surveys. *Nature Methods*, 10(12):1200–1202, December 2013.
- [6] Charity W. Law, Yunshun Chen, Wei Shi, and Gordon K. Smyth. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biology*, 15:R29, January 2014.
- [7] Siddhartha Mandal, Will Van Treuren, Richard A. White, Merete Eggesbø, Rob Knight, and Shyamal D. Peddada. Analysis of composition of microbiomes: a novel method for studying microbial composition. *Microbial Ecology in Health and Disease*, 26, May 2015.
- [8] M. Senthil Kumar, Eric V. Slud, Kwame Okrah, Stephanie C. Hicks, Sridhar Hannenhalli, and Héctor Corrada Bravo. Analysis and correction of compositional bias in sparse sequencing count data. *BMC Genomics*, 19(1):799, November 2018.
- [9] Matthew L Davis, Yuan Huang, and Kai Wang. Rank normalization empowers a t-test for microbiome differential abundance analysis while controlling for false discoveries. *Briefings in Bioinformatics*, 04 2021. bbab059.
- [10] Huijuan Zhou, Xianyang Zhang, Kejun He, and Jun Chen. Linda: Linear models for differential abundance analysis of microbiome compositional data, 2021.
- [11] Charlotte Soneson and Mauro Delorenzi. A comparison of methods for differential expression analysis of RNA-seq data. *BMC Bioinformatics*, 14:91, February 2013.
- [12] Marie-Agnès Dillies, Andrea Rau, Julie Aubert, Christelle Hennequet-Antier, Marine Jeanmougin, Nicolas Servant, Céline Keime, Guillemette Marot, David Castel, Jordi Estelle, Gregory Guernec, Bernd Jagla, Luc Jouneau, Denis Laloë, Caroline Le Gall, Brigitte Schaeffer, Stéphane Le Crom, Mickaël Guedj, Florence Jaffrézic, and French StatOmique Consortium. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. *Briefings in Bioinformatics*, 14(6):671–683, November 2013.
- [13] Jonathan Thorsen, Asker Brejnrod, Martin Mortensen, Morten A. Rasmussen, Jakob Stokholm, Waleed Abu Al-Soud, Søren Sørensen, Hans Bisgaard, and Johannes Waage. Large-scale benchmarking reveals false discoveries and count transformation sensitivity in 16S rRNA gene amplicon data analysis methods used in microbiome studies. *Microbiome*, 4:62, 2016.
- [14] Stijn Hawinkel, Federico Mattiello, Luc Bijnens, and Olivier Thas. A broken promise: microbiome differential abundance methods do not control the false discovery rate. *Briefings in Bioinformatics*, August 2017.
- [15] Sophie Weiss, Zhenjiang Zech Xu, Shyamal Peddada, Amnon Amir, Kyle Bittinger, Antonio Gonzalez, Catherine Lozupone, Jesse R. Zaneveld, Yoshiki Vázquez-Baeza, Amanda Birmingham, Embriette R. Hyde, and Rob Knight. Normalization and microbial differential abundance strategies depend upon data characteristics. *Microbiome*, 5(1):27, March 2017.
- [16] Mariana Buongiorno Pereira, Mikael Wallroth, Viktor Jonsson, and Erik Kristiansson. Comparison of normalization methods for the analysis of metagenomic gene abundance data. *BMC Genomics*, 19(1):274, April 2018.
- [17] Thomas P. Quinn, Tamsyn M. Crowley, and Mark F. Richardson. Benchmarking differential expression analysis tools for RNA-Seq: normalization-based vs. log-ratio transformation-based methods. *BMC Bioinformatics*, 19(1):274, July 2018.

- [18] Paul J. McMurdie and Susan Holmes. Waste Not, Want Not: Why Rarefying Microbiome Data Is Inadmissible. *PLoS Computational Biology*, 10(4):e1003531, April 2014.
- [19] Thomas P. Quinn, Ionas Erb, Mark F. Richardson, and Tamsyn M. Crowley. Understanding sequencing data as compositions: an outlook and review. *Bioinformatics*, 34(16):2870–2878, August 2018.
- [20] Michael R McLaren, Amy D Willis, and Benjamin J Callahan. Consistent and correctable bias in metagenomic sequencing experiments. *eLife*, 8:e46923, September 2019.
- [21] Ira W. Deveson, Wendy Y. Chen, Ted Wong, Simon A. Hardwick, Stacey B. Andersen, Lars K. Nielsen, John S. Mattick, and Tim R. Mercer. Representing genetic variation with synthetic DNA standards. *Nature Methods*, 13(9):784–791, 2016.
- [22] Simon A. Hardwick, Wendy Y. Chen, Ted Wong, Ira W. Deveson, James Blackburn, Stacey B. Andersen, Lars K. Nielsen, John S. Mattick, and Tim R. Mercer. Spliced synthetic genes as internal controls in RNA sequencing experiments. *Nature Methods*, 13(9):792–798, 2016.
- [23] Simon A. Hardwick, Wendy Y. Chen, Ted Wong, Bindu S. Kanakamedala, Ira W. Deveson, Sarah E. Ongley, Nadia S. Santini, Esteban Marcellin, Martin A. Smith, Lars K. Nielsen, Catherine E. Lovelock, Brett A. Neilan, and Tim R. Mercer. Synthetic microbe communities provide internal reference standards for metagenome sequencing and analysis. *Nature Communications*, 9(1):3096, August 2018.
- [24] Andrzej Tkacz, Marion Hortala, and Philip S. Poole. Absolute quantitation of microbiota abundance in environmental samples. *Microbiome*, 6, June 2018.
- [25] Donald T. McKnight, Roger Huerlimann, Deborah S. Bower, Lin Schwarzkopf, Ross A. Alford, and Kyall R. Zenger. Methods for normalizing microbiome data: An ecological perspective. *Methods in Ecology and Evolution*, 10(3):389–400, 2019.
- [26] Jérémie Breda, Mihaela Zavolan, and Erik van Nimwegen. Bayesian inference of the gene expression states of single cells from scRNA-seq data. *bioRxiv*, 2019.
- [27] James T. Morton, Clarisse Marotz, Alex Washburne, Justin Silverman, Livia S. Zaramela, Anna Edlund, Karsten Zengler, and Rob Knight. Establishing microbial composition measurement standards with reference frames. *Nature Communications*, 10(1):1–11, June 2019.
- [28] Thomas P. Quinn, Ionas Erb, Greg Gloor, Cedric Notredame, Mark F. Richardson, and Tamsyn M. Crowley. A field guide for the compositional analysis of any-omics data. *GigaScience*, 8(9), September 2019.
- [29] J Aitchison. *The Statistical Analysis of Compositional Data*. Chapman & Hall, Ltd., London, UK, UK, 1986.
- [30] David R Lovell, Xin-Yi Chua, and Annette McGrath. Counts: an outstanding challenge for log-ratio analysis of compositional data in the molecular biosciences. *NAR Genomics and Bioinformatics*, 2(lqaa040), June 2020.
- [31] K. Gerald van den Boogaart and Raimon Tolosana-Delgado. Fundamental Concepts of Compositional Data Analysis. In *Analyzing Compositional Data with R, Use R!*, pages 13–50. Springer Berlin Heidelberg, 2013.
- [32] Ali Mortazavi, Brian A. Williams, Kenneth McCue, Lorian Schaeffer, and Barbara Wold. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nature Methods*, 5(7):621–628, July 2008.
- [33] J. Aitchison and J. Bacon-Shone. Log contrast models for experiments with mixtures. *Biometrika*, 71(2):323–330, August 1984.
- [34] Mark D. Robinson and Alicia Oshlack. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biology*, 11:R25, 2010.

- [35] Samuel Marguerat, Alexander Schmidt, Sandra Codlin, Wei Chen, Ruedi Aebersold, and Jürg Bähler. Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. *Cell*, 151(3):671–683, October 2012.
- [36] Jia R. Wu, Jean M. Macklaim, Briana L. Genge, and Gregory B. Gloor. Finding the centre: corrections for asymmetry in high-throughput sequencing datasets. *arXiv:1704.01841 [q-bio]*, April 2017. arXiv: 1704.01841.
- [37] Ionas Erb and Cedric Notredame. How should we measure proportionality on relative gene expression data? *Theory in Biosciences*, 135:21–36, 2016.
- [38] Giuliano Netto Flores Cruz, Ana Paula Christoff, and Luiz Felipe Valter de Oliveira. Equivolumetric Protocol Generates Library Sizes Proportional to Total Microbial Load in 16S Amplicon Sequencing. *Frontiers in Microbiology*, 12, 2021.
- [39] Gregory B. Gloor, Jia Rong Wu, Vera Pawlowsky-Glahn, and Juan José Egozcue. It’s all relative: analyzing microbiome data as compositions. *Annals of Epidemiology*, 26(5):322–329, May 2016.
- [40] Gregory B. Gloor, Jean M. Macklaim, Vera Pawlowsky-Glahn, and Juan J. Egozcue. Microbiome Datasets Are Compositional: And This Is Not Optional. *Frontiers in Microbiology*, 8:2224, 2017.
- [41] Pratheepa Jeganathan and Susan P. Holmes. A Statistical Perspective on the Challenges in Molecular Microbial Biology. *arXiv:2103.04198 [stat]*, March 2021. arXiv: 2103.04198.
- [42] Michael Ashburner, Catherine A. Ball, Judith A. Blake, David Botstein, Heather Butler, J. Michael Cherry, Allan P. Davis, Kara Dolinski, Selina S. Dwight, Janan T. Eppig, Midori A. Harris, David P. Hill, Laurie Issel-Tarver, Andrew Kasarskis, Suzanna Lewis, John C. Matese, Joel E. Richardson, Martin Ringwald, Gerald M. Rubin, and Gavin Sherlock. Gene Ontology: tool for the unification of biology. *Nature Genetics*, 25(1):25–29, May 2000.
- [43] M. Kanehisa and S. Goto. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Research*, 28(1):27–30, January 2000.
- [44] Pankaj Trivedi, Jan E. Leach, Susannah G. Tringe, Tongmin Sa, and Brajesh K. Singh. Plant–microbiome interactions: from community assembly to plant health. *Nature Reviews Microbiology*, 18(11):607–621, November 2020.
- [45] James E. McDonald, Julian R. Marchesi, and Britt Koskella. Application of ecological and evolutionary theory to microbiome community dynamics across systems. *Proceedings of the Royal Society B: Biological Sciences*, 287(1941):20202886, December 2020.
- [46] J. J. Elser, R. W. Sterner, E. Gorokhova, W. F. Fagan, T. A. Markow, J. B. Cotner, J. F. Harrison, S. E. Hobbie, G. M. Odell, and L. W. Weider. Biological stoichiometry from genes to ecosystems. *Ecology Letters*, 3(6):540–550, 2000.
- [47] Olivia Padovan-Merhar, Gautham P. Nair, Andrew G. Biaesch, Andreas Mayer, Steven Scarfone, Shawn W. Foley, Angela R. Wu, L. Stirling Churchman, Abhyudai Singh, and Arjun Raj. Single mammalian cells compensate for differences in cellular volume and DNA copy number through independent global transcriptional mechanisms. *Molecular Cell*, 58(2):339–352, April 2015.
- [48] James A. Birchler and Reiner A. Veitia. The gene balance hypothesis: implications for gene regulation, quantitative traits and evolution. *New Phytologist*, 186(1):54–62, April 2010.
- [49] James A. Birchler and Reiner A. Veitia. Gene balance hypothesis: Connecting issues of dosage sensitivity across biological disciplines. *Proceedings of the National Academy of Sciences*, page 201207726, August 2012.
- [50] James J. Elser, John D. Nagy, and Yang Kuang. Biological Stoichiometry: An Ecological Perspective on Tumor Dynamics. *BioScience*, 53(11):1112–1120, November 2003.
- [51] M. O. Hill. Diversity and Evenness: A Unifying Notation and Its Consequences. *Ecology*, 54(2):427–432, 1973.

- [52] Curtis Huttenhower, Dirk Gevers, Rob Knight, Sahar Abubucker, Jonathan H. Badger, Asif T. Chinwalla, Heather H. Creasy, Ashlee M. Earl, Michael G. FitzGerald, Robert S. Fulton, Michelle G. Giglio, Kymberlie Hallsworth-Pepin, Elizabeth A. Lobos, Ramana Madupu, Vincent Magrini, John C. Martin, Makedonka Mitreva, Donna M. Muzny, Erica J. Sodergren, James Versalovic, Aye M. Wollam, Kim C. Worley, Jennifer R. Wortman, Sarah K. Young, Qiandong Zeng, Kjersti M. Aagaard, Olukemi O. Abolude, Emma Allen-Vercoe, Eric J. Alm, Lucia Alvarado, Gary L. Andersen, Scott Anderson, Elizabeth Appelbaum, Harindra M. Arachchi, Gary Armitage, Cesar A. Arze, Tulin Ayvaz, Carl C. Baker, Lisa Begg, Tsegahiwot Belachew, Veena Bhonagiri, Monika Bihan, Martin J. Blaser, Toby Bloom, Vivien Bonazzi, J. Paul Brooks, Gregory A. Buck, Christian J. Buhay, Dana A. Busam, Joseph L. Campbell, Shane R. Canon, Brandi L. Cantarel, Patrick S. G. Chain, I-Min A. Chen, Lei Chen, Shaila Chhibba, Ken Chu, Dawn M. Ciulla, Jose C. Clemente, Sandra W. Clifton, Sean Conlan, Jonathan Crabtree, Mary A. Cutting, Noam J. Davidovics, Catherine C. Davis, Todd Z. DeSantis, Carolyn Deal, Kimberley D. Delehaunty, Floyd E. Dewhirst, Elena Deych, Yan Ding, David J. Dooling, Shannon P. Dugan, Wm Michael Dunne, A. Scott Durkin, Robert C. Edgar, Rachel L. Erlich, Candace N. Farmer, Ruth M. Farrell, Karoline Faust, Michael Feldgarden, Victor M. Felix, Sheila Fisher, Anthony A. Fodor, Larry J. Forney, Leslie Foster, Valentina Di Francesco, Jonathan Friedman, Dennis C. Friedrich, Catrina C. Fronick, Lucinda L. Fulton, Hongyu Gao, Nathalia Garcia, Georgia Giannoukos, Christina Giblin, Maria Y. Giovanni, Jonathan M. Goldberg, Johannes Goll, Antonio Gonzalez, Allison Griggs, Sharvari Gujja, Susan Kinder Haake, Brian J. Haas, Holli A. Hamilton, Emily L. Harris, Theresa A. Hepburn, Brandi Herter, Diane E. Hoffmann, Michael E. Holder, Clinton Howarth, Katherine H. Huang, Susan M. Huse, Jacques Izard, Janet K. Jansson, Huaiyang Jiang, Catherine Jordan, Vandita Joshi, James A. Katancik, Wendy A. Keitel, Scott T. Kelley, Cristyn Kells, Nicholas B. King, Dan Knights, Heidi H. Kong, Omry Koren, Sergey Koren, Karthik C. Kota, Christie L. Kovar, Nikos C. Kyrpides, Patricio S. La Rosa, Sandra L. Lee, Katherine P. Lemon, Niall Lennon, Cecil M. Lewis, Lora Lewis, Ruth E. Ley, Kelvin Li, Konstantinos Liolios, Bo Liu, Yue Liu, Chien-Chi Lo, Catherine A. Lozupone, R. Dwayne Lunsford, Tessa Madden, Anup A. Mahurkar, Peter J. Mannon, Elaine R. Mardis, Victor M. Markowitz, Konstantinos Mavromatis, Jamiison M. McCarrison, Daniel McDonald, Jean McEwen, Amy L. McGuire, Pamela McInnes, Teena Mehta, Kathie A. Mihindukulasuriya, Jason R. Miller, Patrick J. Minx, Irene Newsham, Chad Nusbaum, Michelle O’Laughlin, Joshua Orvis, Ioanna Pagani, Krishna Palaniappan, Shital M. Patel, Matthew Pearson, Jane Peterson, Mircea Podar, Craig Pohl, Katherine S. Pollard, Mihai Pop, Margaret E. Priest, Lita M. Proctor, Xiang Qin, Jeroen Raes, Jacques Ravel, Jeffrey G. Reid, Mina Rho, Rosamond Rhodes, Kevin P. Riehle, Maria C. Rivera, Beltran Rodriguez-Mueller, Yu-Hui Rogers, Matthew C. Ross, Carsten Russ, Ravi K. Sanka, Pamela Sankar, J. Fah Sathirapongsasuti, Jeffery A. Schloss, Patrick D. Schloss, Thomas M. Schmidt, Matthew Scholz, Lynn Schriml, Alyxandria M. Schubert, Nicola Segata, Julia A. Segre, William D. Shannon, Richard R. Sharp, Thomas J. Sharpton, Narmada Shenoy, Nihar U. Sheth, Gina A. Simone, Indresh Singh, Christopher S. Smillie, Jack D. Sobel, Daniel D. Sommer, Paul Spicer, Granger G. Sutton, Sean M. Sykes, Diana G. Tabbaa, Mathangi Thiagarajan, Chad M. Tomlinson, Manolito Torralba, Todd J. Treangen, Rebecca M. Truty, Tatiana A. Vishnivetskaya, Jason Walker, Lu Wang, Zhengyuan Wang, Doyle V. Ward, Wesley Warren, Mark A. Watson, Christopher Wellington, Kris A. Wetterstrand, James R. White, Katarzyna Wilczek-Boney, YuanQing Wu, Kristine M. Wylie, Todd Wylie, Chandri Yandava, Liang Ye, Yuzhen Ye, Shibu Yooseph, Bonnie P. Youmans, Lan Zhang, Yanjiao Zhou, Yiming Zhu, Laurie Zoloth, Jeremy D. Zucker, Bruce W. Birren, Richard A. Gibbs, Sarah K. Highlander, Barbara A. Methé, Karen E. Nelson, Joseph F. Petrosino, George M. Weinstock, Richard K. Wilson, Owen White, and The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature*, 486(7402):207–214, June 2012.
- [53] Louise Crovesy, Daniele Masterson, and Eliane Lopes Rosado. Profile of the gut microbiota of adults with obesity: a systematic review. *European Journal of Clinical Nutrition*, 74(9):1251–1262, September 2020.
- [54] Fabien Magne, Martin Gotteland, Lea Gauthier, Alejandra Zazueta, Susana Pesoa, Paola Navarrete, and Ramadass Balamurugan. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? *Nutrients*, 12(5), May 2020.

- [55] Caitlin V. Hall, Anton Lord, Richard Betzel, Martha Zakrzewski, Lisa A. Simms, Andrew Zalesky, Graham Radford-Smith, and Luca Cocchi. Co-existence of Network Architectures Supporting the Human Gut Microbiome. *iScience*, 22:380–391, December 2019.
- [56] Peter Langfelder and Steve Horvath. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*, 9:559, 2008.
- [57] Antoine Bodein, Olivier Chapleur, Arnaud Droit, and Kim-Anh Lê Cao. A Generic Multivariate Framework for the Integration of Microbiome Longitudinal Studies With Other Data Types. *Frontiers in Genetics*, 10, 2019.
- [58] Adham Beykikhoshk, Thomas P. Quinn, Samuel C. Lee, Truyen Tran, and Svetha Venkatesh. DeepTRIAGE: interpretable and individualised biomarker scores using attention mechanism for the classification of breast cancer sub-types. *BMC Medical Genomics*, 13(3):20, February 2020.
- [59] James T. Morton, Jon Sanders, Robert A. Quinn, Daniel McDonald, Antonio Gonzalez, Yoshiki Vázquez-Baeza, Jose A. Navas-Molina, Se Jin Song, Jessica L. Metcalf, Embriette R. Hyde, Manuel Lladser, Pieter C. Dorrestein, and Rob Knight. Balance Trees Reveal Microbial Niche Differentiation. *mSystems*, 2(1):e00162–16, February 2017.
- [60] Justin D. Silverman, Alex D. Washburne, Sayan Mukherjee, and Lawrence A. David. A phylogenetic transform enhances analysis of compositional microbiota data. *eLife*, 6:e21887, 2017.
- [61] Alex D. Washburne, Justin D. Silverman, Jonathan W. Leff, Dominic J. Bennett, John L. Darcy, Sayan Mukherjee, Noah Fierer, and Lawrence A. David. Phylogenetic factorization of compositional data yields lineage-level associations in microbiome datasets. *PeerJ*, 5:e2969, 2017.
- [62] J. Rivera-Pinto, J. J. Egozcue, V. Pawlowsky-Glahn, R. Paredes, M. Noguera-Julian, and M. L. Calle. Balances: a New Perspective for Microbiome Analysis. *mSystems*, 3(4):e00053–18, August 2018.
- [63] M. Luz Calle. Statistical Analysis of Metagenomics Data. *Genomics & Informatics*, 17(1):e6, March 2019.
- [64] Thomas P. Quinn and Ionas Erb. Interpretable Log Contrasts for the Classification of Health Biomarkers: a New Approach to Balance Selection. *mSystems*, 5(2):e00230–19, April 2020.
- [65] Jan Walach, Peter Filzmoser, Karel Hron, Beata Walczak, and Lukáš Najdekr. Robust biomarker identification in a two-class problem based on pairwise log-ratios. *Chemometrics and Intelligent Laboratory Systems*, 171:277–285, December 2017.
- [66] Ionas Erb, Thomas Quinn, David Lovell, and Cedric Notredame. Differential proportionality - a normalization-free approach to differential gene expression. *bioRxiv*, page 134536, March 2018.
- [67] J. J. Egozcue and V. Pawlowsky-Glahn. Groups of Parts and Their Balances in Compositional Data Analysis. *Mathematical Geology*, 37(7):795–828, October 2005.
- [68] J. J. Egozcue, V. Pawlowsky-Glahn, G. Mateu-Figueras, and C. Barceló-Vidal. Isometric Logratio Transformations for Compositional Data Analysis. *Mathematical Geology*, 35(3):279–300, April 2003.
- [69] Vera Pawlowsky-Glahn, Juan José Egozcue, and Raimon Tolosana Delgado. Principal balances. *Proceedings of CoDaWork 2011, The 4th Compositional Data Analysis Workshop*, pages 1–10, 2011.
- [70] Antoni Susin, Yiwen Wang, Kim-Anh Lê Cao, and M. Luz Calle. Variable selection in microbiome compositional data analysis. *NAR Genomics and Bioinformatics*, 2(2), June 2020.
- [71] Elliott Gordon-Rodriguez, Thomas P. Quinn, and John P. Cunningham. Learning Sparse Log-Ratios for High-Throughput Sequencing Data. *bioRxiv*, page 2021.02.11.430695, February 2021.

- [72] Leo Breiman. Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author). *Statistical Science*, 16(3):199–231, August 2001.
- [73] Michael Greenacre. Amalgamations are valid in compositional data analysis, can be used in agglomerative clustering, and their logratios have an inverse transformation. *Applied Computing and Geosciences*, 5:100017, March 2020.
- [74] Michael Greenacre, Eric Grunsky, and John Bacon-Shone. A comparison of isometric and amalgamation logratio balances in compositional data analysis. *Computers & Geosciences*, 148:104621, March 2021.
- [75] Michael Greenacre and Eric Grunsky. The isometric logratio transformation in compositional data analysis: a practical evaluation. Technical Report 1627, Department of Economics and Business, Universitat Pompeu Fabra, January 2019.
- [76] Thomas P Quinn and Ionas Erb. Amalgams: data-driven amalgamation for the dimensionality reduction of compositional data. *NAR Genomics and Bioinformatics*, 2(lqaa076), December 2020.
- [77] Agnieszka Smolinska, Danyta I. Tedjo, Lionel Blanchet, Alexander Bodelier, Marieke J. Pierik, Ad A. M. Masclee, Jan Dallinga, Paul H. M. Savelkoul, Daisy M. A. E. Jonkers, John Penders, and Frederik-Jan van Schooten. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients. *Analytica Chimica Acta*, 1025:1–11, September 2018.
- [78] Zheng-Zheng Tang, Guanhua Chen, Qilin Hong, Shi Huang, Holly M. Smith, Rachana D. Shah, Matthew Scholz, and Jane F. Ferguson. Multi-Omic Analysis of the Microbiome and Metabolome in Healthy Subjects Reveals Microbiome-Dependent Relationships Between Diet and Metabolites. *Frontiers in Genetics*, 10, 2019.
- [79] Jason Lloyd-Price, Cesar Arze, Ashwin N. Ananthakrishnan, Melanie Schirmer, Julian Avila-Pacheco, Tiffany W. Poon, Elizabeth Andrews, Nadim J. Ajami, Kevin S. Bonham, Colin J. Brislawn, David Casero, Holly Courtney, Antonio Gonzalez, Thomas G. Graeber, A. Brantley Hall, Kathleen Lake, Carol J. Landers, Himel Mallick, Damian R. Plichta, Mahadev Prasad, Gholamali Rahnavard, Jenny Sauk, Dmitry Shungin, Yoshiki Vázquez-Baeza, Richard A. White, Jonathan Braun, Lee A. Denson, Janet K. Jansson, Rob Knight, Subra Kugathasan, Dermot P. B. McGovern, Joseph F. Petrosino, Thaddeus S. Stappenbeck, Harland S. Winter, Clary B. Clish, Eric A. Franzosa, Hera Vlamakis, Ramnik J. Xavier, and Curtis Huttenhower. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature*, 569(7758):655, May 2019.
- [80] Shinichi Yachida, Sayaka Mizutani, Hirotsugu Shiroma, Satoshi Shiba, Takeshi Nakajima, Taku Sakamoto, Hikaru Watanabe, Keigo Masuda, Yuichiro Nishimoto, Masaru Kubo, Fumie Hosoda, Hirofumi Rokutan, Minoru Matsumoto, Hiroyuki Takamaru, Masayoshi Yamada, Takahisa Matsuda, Motoki Iwasaki, Taiki Yamaji, Tatsuo Yachida, Tomoyoshi Soga, Ken Kurokawa, Atsushi Toyoda, Yoshitoshi Ogura, Tetsuya Hayashi, Masanori Hatakeyama, Hitoshi Nakagama, Yutaka Saito, Shinji Fukuda, Tatsuhiro Shibata, and Takuji Yamada. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. *Nature Medicine*, 25(6):968, June 2019.
- [81] Eric A. Franzosa, Alexandra Sirota-Madi, Julian Avila-Pacheco, Nadine Fornelos, Henry J. Haiser, Stefan Reinker, Tommi Vatanen, A. Brantley Hall, Himel Mallick, Lauren J. McIver, Jenny S. Sauk, Robin G. Wilson, Betsy W. Stevens, Justin M. Scott, Kerry Pierce, Amy A. Deik, Kevin Bullock, Floris Imhann, Jeffrey A. Porter, Alexandra Zhernakova, Jingyuan Fu, Rinse K. Weersma, Cisca Wijmenga, Clary B. Clish, Hera Vlamakis, Curtis Huttenhower, and Ramnik J. Xavier. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nature Microbiology*, 4(2):293–305, 2019.
- [82] Kim-Anh Lê Cao, Debra Rossouw, Christèle Robert-Granié, and Philippe Besse. A sparse PLS for variable selection when integrating omics data. *Statistical Applications in Genetics and Molecular Biology*, 7(1):Article 35, 2008.

- [83] Kim-Anh Lê Cao, Simon Boitard, and Philippe Besse. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. *BMC Bioinformatics*, 12(1):253, June 2011.
- [84] Chen Meng, Oana A. Zeleznik, Gerhard G. Thallinger, Bernhard Kuster, Amin M. Gholami, and Aedín C. Culhane. Dimension reduction techniques for the integrative analysis of multi-omics data. *Briefings in Bioinformatics*, 17(4):628–641, 2016.
- [85] O. Paliy and V. Shankar. Application of multivariate statistical techniques in microbial ecology. *Molecular Ecology*, 25(5):1032–1057, March 2016.
- [86] James T. Morton, Alexander A. Aksenov, Louis Felix Nothias, James R. Foulds, Robert A. Quinn, Michelle H. Badri, Tami L. Swenson, Marc W. Van Goethem, Trent R. Northen, Yoshiki Vazquez-Baeza, Mingxun Wang, Nicholas A. Bokulich, Aaron Watters, Se Jin Song, Richard Bonneau, Pieter C. Dorrestein, and Rob Knight. Learning representations of microbe–metabolite interactions. *Nature Methods*, pages 1–9, November 2019.
- [87] Vuong Le, Thomas P. Quinn, Truyen Tran, and Svetha Venkatesh. Deep in the Bowel: Highly Interpretable Neural Encoder-Decoder Networks Predict Gut Metabolites from Gut Microbiome. *BMC Genomics*, 21(4):256, July 2020.
- [88] Thomas P. Quinn and Ionas Erb. Examining microbe–metabolite correlations by linear methods. *Nature Methods*, 18(1):37–39, January 2021.
- [89] Sugnet Lubbe, Peter Filzmoser, and Matthias Templ. Comparison of zero replacement strategies for compositional data with large numbers of zeros. *Chemometrics and Intelligent Laboratory Systems*, 210:104248, March 2021.
- [90] Florian Rohart, Benoît Gautier, Amrit Singh, and Kim-Anh Lê Cao. mixOmics: An R package for ‘omics feature selection and multiple data integration. *PLoS Computational Biology*, 13(11):e1005752, November 2017.